The resubmission of the NDA for Etripamil by Milestone Pharmaceuticals is a pivotal development, indicating progress towards regulatory approval. This news is likely to be viewed positively by investors, as it moves the company closer to potentially bringing a new treatment to market. The direct mention of the company and its drug highlights the significance of this event for Milestone Pharmaceuticals, suggesting a positive short-term impact on its stock price.